Literature DB >> 27113097

Design, synthesis, and biological characterization of tamibarotene analogs as anticancer agents.

Yuqi Jiang1, Xiaoyang Li1, Xue Wang1, Zhonglan Wang1, Jian Zhang2, Jingde Wu3, Wenfang Xu4.   

Abstract

In our efforts of developing novel compounds as potential anticancer agents, a series of tamibarotene analogs containing Zn(2+) -binding moieties were designed and developed. Biological characterization identified compound 7b as the most potent one with improved antiproliferative activities against multiple cancer cell lines, compared to parent compound tamibarotene. Further characterization also demonstrated that compound 7b exhibited moderate activities as a histone deacetylase inhibitor with IC50 of 1.8 ± 0.1 μm, thus suggesting that this could contribute to the improved antiproliferative activities of 7b. Pharmacokinetic studies revealed that compound 7b could release tamibarotene after administration and prolong the circulation time of tamibarotene, and this may also potentially contribute to the improved antiproliferative activities. Collectively, the results demonstrated that compound 7b could serve as a new lead for further development of more potent analogs as potential anticancer agents.
© 2016 John Wiley & Sons A/S.

Entities:  

Keywords:  anticancer; histone deacetylases; multitarget drugs; retinoids; tamibarotene

Mesh:

Substances:

Year:  2016        PMID: 27113097     DOI: 10.1111/cbdd.12778

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  2 in total

Review 1.  Retinoic Acid Receptors in Acute Myeloid Leukemia Therapy.

Authors:  Orsola di Martino; John S Welch
Journal:  Cancers (Basel)       Date:  2019-12-01       Impact factor: 6.639

2.  Reduction BACE1 expression via suppressing NF-κB mediated signaling by Tamibarotene in a mouse model of Alzheimer's disease.

Authors:  Aimin Qiao; Jieyi Li; Yaohua Hu; Jinquan Wang; Zizhuo Zhao
Journal:  IBRO Neurosci Rep       Date:  2021-02-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.